Private Advisor Group LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 201,053 shares of the company’s stock after buying an additional 8,976 shares during the period. Johnson & Johnson makes up 0.8% of Private Advisor Group LLC’s holdings, making the stock its 18th largest position. Private Advisor Group LLC’s holdings in Johnson & Johnson were worth $23,067,000 as of its most recent filing with the SEC.
Other institutional investors have also bought and sold shares of the company. Putnam FL Investment Management Co. raised its position in Johnson & Johnson by 213.8% in the third quarter. Putnam FL Investment Management Co. now owns 40,875 shares of the company’s stock valued at $4,829,000 after buying an additional 27,850 shares during the period. Korea Investment CORP raised its position in Johnson & Johnson by 14.0% in the third quarter. Korea Investment CORP now owns 1,486,570 shares of the company’s stock valued at $175,609,000 after buying an additional 182,730 shares during the period. State of New Jersey Common Pension Fund D raised its position in Johnson & Johnson by 2.5% in the third quarter. State of New Jersey Common Pension Fund D now owns 2,951,000 shares of the company’s stock valued at $348,602,000 after buying an additional 71,000 shares during the period. Tesco Pension Investment Ltd acquired a new position in Johnson & Johnson during the third quarter valued at approximately $148,524,000. Finally, Clean Yield Group raised its position in Johnson & Johnson by 0.6% in the third quarter. Clean Yield Group now owns 57,916 shares of the company’s stock valued at $6,842,000 after buying an additional 317 shares during the period. 65.30% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson (NYSE:JNJ) opened at 128.07 on Tuesday. Johnson & Johnson has a 12-month low of $106.36 and a 12-month high of $129.00. The company’s 50 day moving average price is $119.96 and its 200-day moving average price is $117.07. The stock has a market cap of $347.50 billion, a price-to-earnings ratio of 21.59 and a beta of 0.74.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, January 24th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.56 by $0.02. Johnson & Johnson had a return on equity of 25.61% and a net margin of 22.78%. The firm had revenue of $18.10 billion for the quarter, compared to analysts’ expectations of $18.28 billion. During the same period in the previous year, the firm earned $1.44 earnings per share. The business’s revenue was up 1.7% compared to the same quarter last year. On average, analysts forecast that Johnson & Johnson will post $7.04 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 14th. Stockholders of record on Tuesday, February 28th were paid a dividend of $0.80 per share. The ex-dividend date of this dividend was Friday, February 24th. This represents a $3.20 annualized dividend and a dividend yield of 2.50%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 54.42%.
Your IP Address:
Several brokerages have issued reports on JNJ. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $121.63 price objective on the stock in a report on Monday, January 9th. Zacks Investment Research raised Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Monday, January 9th. Royal Bank of Canada dropped their price objective on Johnson & Johnson from $133.00 to $128.00 and set an “outperform” rating on the stock in a report on Wednesday, January 25th. Goldman Sachs Group Inc dropped their price objective on Johnson & Johnson from $120.00 to $115.00 and set a “neutral” rating on the stock in a report on Wednesday, January 25th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and set a $132.00 price objective (up previously from $125.00) on shares of Johnson & Johnson in a report on Saturday, March 11th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and six have issued a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Hold” and an average price target of $124.09.
In other news, VP Paulus Stoffels sold 22,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 15th. The stock was sold at an average price of $117.29, for a total transaction of $2,580,380.00. Following the transaction, the vice president now directly owns 127,650 shares of the company’s stock, valued at $14,972,068.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.11% of the stock is currently owned by insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.